4D Molecular Therapeutics Appoints Susannah Gray to Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced the appointment of Susannah Gray to the Board of Directors. Ms. Gray brings more than 30 years of biopharmaceutical experience specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC. “Susannah’s extensive knowledge

Click to view original post